PharmiWeb Today Story
- The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely.
- Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics.
- This approach could potentially be adapted for diagnosis of other neurological conditions.
WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
Julie Sawyer Montgomery, Vice President and Group Executive, Danaher Diagnostics, said: "Our latest in vitro diagnostics innovations are improving the detection of specific biomarkers found in blood when brain cells are damaged. We are thrilled to partner with Johns Hopkins with the goal of leveraging these solutions to develop tests for earlier and more precise diagnosis of mild TBI, which could ultimately lead to improved treatment outcomes and faster recovery for patients."
Nearly 56 million mild TBI patients worldwide could benefit from a more precise approach to diagnosis1. While computed tomography (CT) is used to visualize tissue damage and diagno…
Read More...Articles
How AI is Transforming Regulatory Affairs
08-May-2024
Top 6 Pharmaceutical Companies in the UK 2024
30-Apr-2024
What Does a Clinical SAS Programmer Do?
16-Apr-2024
Featured Events
-
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
Pharma USA 2022
16-Mar-2022 - 17-Mar-2022 -
Reuters Events: Pharma 2022
11-Oct-2022 - 13-Oct-2022 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023 -
Reuters Events: Pharma USA 2023
28-Mar-2023 - 29-Mar-2023
News
-
Applied DNA Regains Compliance with Nasdaq Minimum…
10-May-2024 -
Veradigm Payerpath Rated Highest in Client Satisfa…
10-May-2024 -
Insights into the $305.7+ Billion Medical Rehabili…
10-May-2024 -
Xenetic Biosciences, Inc. Reports First Quarter 20…
10-May-2024 -
Orthodontics Market Trends: Growth Trajectory Poin…
10-May-2024 -
The Plus SideZ: Ozempic Health & Wellness Educatio…
10-May-2024